ARTICLE | Politics, Policy & Law

Sharpless' homecoming: the NCI chief's lessons from his time at FDA

NCI's Sharpless on personalized therapies, AI diagnostics, funding trends and what he learned at FDA

February 18, 2020 10:28 PM UTC
Updated on Feb 19, 2020 at 3:33 PM UTC

NCI Director Ned Sharpless has returned from his seven month stint as acting FDA Commissioner aiming to take on the regulatory hurdles that lie ahead for promising technologies, and seeking ways for NCI's grants to make the most of the flood of innovation in oncology.

In a conversation with BioCentury, Norman "Ned" Sharpless said his time at FDA made it clear that NIH’s National Cancer Institute (NCI) has a role to play in supporting regulatory innovations to facilitate the approval and reimbursement of key technologies that could transform cancer treatment...

BCIQ Company Profiles

National Cancer Institute